High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Early Alzheimer's Disease
NCT04599764, Not applicable, Completed, Anhui Medical University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Early Alzheimer's Disease | ClinicalTrials.gov |
| NCT number | NCT04599764 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 60 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Anhui Medical University | ClinicalTrials.gov |
| Conditions | Transcranial Direct Current Stimulation, Functional Magnetic Resonance Imaging, Early Alzheimer's Disease | ClinicalTrials.gov |
| Interventions | HD-tDCS, computer-based cognitive training, Sham tDCS, Control cognitive training | ClinicalTrials.gov |
| First posted | 2020-10-23 | ClinicalTrials.gov |
| Last updated | 2026-10-07 | ClinicalTrials.gov |
Registered outcomes 16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Changes assessed by Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) | changes from baseline at 14 days and 12 weeks post-treatment | This is an very common clinical motor estimating scale. including orientation, language, structure, application of concepts, immediate recall of words and recognition of words, with a full score of 70. Higher scores indicate worse symptoms. | ClinicalTrials.gov |
| Secondary | special-version working memory | changes from baseline at 14 days and 4,12 weeks post-treatment | the accuracy and reaction time in working memory task | ClinicalTrials.gov |
| Secondary | Associative Memory | changes from baseline at 14 days and 4,12 weeks post-treatment | The changes in Associative Memory will constitute the major research outcome measure used to assess response to HD-tDCS. | ClinicalTrials.gov |
| Secondary | MMSE(Mini Mental State Examination) | changes from baseline at 14 days and 4,12 weeks post-treatment | The full name of MMSE is mini-mental state examination, and the scale consists of 30 subject, include the following seven aspects: time orientation, place orientation,immediate memory,attention and calculation,delay memory,language, visual space.One point is awarded for each question correctly answered during MMSE evaluation. If subject give the wrong answer or don't know answe he/she awarded 0 score, scope of scale score of 0 to 30 points. The higher the score, the better. | ClinicalTrials.gov |
| Secondary | LMT (Logic Memory Test) | changes from baseline at 7,14 days and 4,12 weeks post-treatment | The changes in LMT will constitute the secondary research outcome | ClinicalTrials.gov |
| Other | DST (Digital Span Test; Forward and Backward) | changes from baseline at 14 days and 4,12 weeks post-treatment | The changes in DST will constitute the other research outcome. | ClinicalTrials.gov |
| Other | TMT (Trail Making Test) | changes from baseline at 14 days and 4,12 weeks post-treatment | The Trail Making Test (TMT) is divided into two parts, part A and part B. Part A requires the subject to connect 25 Numbers on the paper in sequence, and part B requires the subject to connect 25 Numbers of different colors alternately in sequence. The time it takes for the subject to complete all the Numbers is the subject's final score. | ClinicalTrials.gov |
| Other | HAMD (Hamilton Depression Scale) | changes from baseline at 14 days and 4,12 weeks post-treatment | The changes in HAMD will constitute the other research outcome. The examination content consists of 17 questions (about 10 minutes), with a full score of 52. The higher the score, the more severe the depressive symptoms are. | ClinicalTrials.gov |
| Other | HAMA (Hamilton Anxiety Scale) | changes from baseline at 14 days and 4,12 weeks post-treatment | The changes in HAMD will constitute the other research outcome. The examination content consists of 14 questions (about 10 minutes), with a full score of 56. The higher the score, the more severe the anxiety symptoms are. | ClinicalTrials.gov |
| Other | NPI (Neuropsychiatric Inventory) | changes from baseline at 14 days and 4,12 weeks post-treatment | The changes in HAMD will constitute the other research outcome. | ClinicalTrials.gov |
| Other | MRI measures | changes from baseline at 14 days and 4,12 weeks post-treatment | Multimodal magnetic resonance data were acquired, including structural phase magnetic resonance and rest state magnetic resonance. | ClinicalTrials.gov |
| Other | changes in Montreal Cognitive Assessment (MoCA) | changes from baseline at 14 days and 4,12 weeks post-treatment | MoCA was developed by Nasreddine et al. based on clinical experience and reference to the MMSE cognitive items and scores, and the final version was finalized in November 2004. We adopted a localized version (Mandarin version，includes 2 alternative versions) in line with the Chinese cultural background.It includes 11 inspection items in 8 cognitive fields, including visual structure skills, executive function, naming, attention and calculation, language, abstract thinking, memory, and orientation. With a total score of 30 or more than 26, it is normal. Anyone who has been education for less than 12 years will need to add one point to his final score. | ClinicalTrials.gov |
| Other | GDS(Geriatric depression scale) | changes from baseline at 14 days and 4,12 weeks post-treatment | The Geriatric Depression Scale (GDS) was created in 1982 by Brank et al. and is dedicated to screening for depression in the elderly. The most suitable feelings for the elderly in the past week were evaluated.There are 30 items in the scale, the total score is 30 points. The higher the score, the more obvious the depressive symptoms. It is generally considered that less than 10 points is normal. | ClinicalTrials.gov |
| Other | JLOT(Judgment of line Judgment of line orientation test orientation test) | changes from baseline at 14 days and 4,12 weeks post-treatment | The JLOT test was determined by Benton et al. in 1994. There are two versions of H and V. The difference is that the order in which the pictures are presented is different. Each version contains 35 images, of which the official test consists of 30 images, and the other 5 images are for the participants to learn. The final score is the correct number of subjects to answer, the full score is 30 points, the higher the score, the better the space perception ability of the subject. | ClinicalTrials.gov |
| Other | HVOT(Hooper visual organization test Hooper visual organization test) | changes from baseline at 14 days and 4,12 weeks post-treatment | The changes in HVOT(Hooper visual organization test Hooper visual organization test) will constitute assess response to rTMS the secondary research outcome measure.HVOT is a cognitive test used to evaluate the perceived structure of the subject. It consists of 30 items，and each question is 1 point and the total score is 30 points. The final score is the correct number of subjects to answer, the full score is 30 points, the higher the score, the better the space perception ability of the subject. | ClinicalTrials.gov |
| Other | The Stroop color test | changes from baseline at 14 days and 4,12 weeks post-treatment | The Stroop color word test was developed by Stroop in 1935 and is used to evaluate the attention function of the subject. The subject is required to correctly read the target color on the stimulus card and record the completion time. The final completion time is the score of the participant. The shorter the time used, the better the performance of the subjects. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Line Angle Matching | Other outcome | ConductCognition |
| Stroop Color-Word Test | Other outcome | ConductCognition |
| Trail Making Test A | Other outcome | ConductCognition |
| Trail Making Test B | Other outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)